Titleist Asset Management LLC Sells 18,528 Shares of Moderna, Inc. (NASDAQ:MRNA)

Titleist Asset Management LLC reduced its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 37.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 31,522 shares of the company's stock after selling 18,528 shares during the quarter. Titleist Asset Management LLC's holdings in Moderna were worth $1,311,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Allworth Financial LP grew its position in shares of Moderna by 17.3% in the fourth quarter. Allworth Financial LP now owns 1,901 shares of the company's stock valued at $73,000 after purchasing an additional 281 shares during the last quarter. Howard Capital Management Inc. boosted its stake in Moderna by 3.1% during the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company's stock valued at $416,000 after purchasing an additional 297 shares during the period. Commonwealth Equity Services LLC grew its holdings in Moderna by 0.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company's stock valued at $3,099,000 after buying an additional 345 shares during the last quarter. Larson Financial Group LLC increased its position in Moderna by 39.1% in the 4th quarter. Larson Financial Group LLC now owns 1,266 shares of the company's stock worth $53,000 after buying an additional 356 shares during the period. Finally, New Insight Wealth Advisors lifted its holdings in shares of Moderna by 4.4% during the fourth quarter. New Insight Wealth Advisors now owns 8,545 shares of the company's stock worth $355,000 after buying an additional 358 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Moderna Trading Up 4.7 %

Shares of Moderna stock traded up $1.16 during mid-day trading on Friday, reaching $25.66. 5,995,360 shares of the stock were exchanged, compared to its average volume of 11,666,958. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The company has a market cap of $9.92 billion, a price-to-earnings ratio of -2.77 and a beta of 2.23. The firm has a 50-day simple moving average of $31.72 and a 200 day simple moving average of $41.27.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MRNA shares. The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. JPMorgan Chase & Co. dropped their price objective on shares of Moderna from $40.00 to $33.00 and set an "underweight" rating on the stock in a report on Friday, March 21st. Argus lowered shares of Moderna from a "buy" rating to a "hold" rating in a research report on Wednesday, December 18th. Barclays downgraded Moderna from an "overweight" rating to an "equal weight" rating and decreased their target price for the stock from $111.00 to $45.00 in a research report on Tuesday, February 18th. Finally, UBS Group cut their price target on Moderna from $96.00 to $78.00 and set a "buy" rating for the company in a report on Wednesday, February 19th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.